Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 616

1.

A resveratrol analog termed 3,3',4,4',5,5'-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor.

Han YS, Quashie P, Mesplède T, Xu H, Quan Y, Jaeger W, Szekeres T, Wainberg MA.

J Med Virol. 2015 May 18. doi: 10.1002/jmv.24271. [Epub ahead of print]

PMID:
25989218
2.

Will drug resistance against dolutegravir in initial therapy ever occur?

Wainberg MA, Han YS.

Front Pharmacol. 2015 Apr 29;6:90. doi: 10.3389/fphar.2015.00090. eCollection 2015. Review.

3.

Limonoids with Anti-HIV Activity from Cipadessa cinerascens.

Yu JH, Wang GC, Han YS, Wu Y, Wainberg MA, Yue JM.

J Nat Prod. 2015 May 13. [Epub ahead of print]

PMID:
25970729
4.

Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis.

Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal ES, Mahuteau-Betzer F, Najman R, Fornarelli P, Tantale K, Basyuk E, Séveno M, Venables JP, Pau B, Bertrand E, Wainberg MA, Speck RF, Scherrer D, Tazi J.

Retrovirology. 2015 Apr 9;12:30. doi: 10.1186/s12977-015-0159-3.

5.

Dolutegravir inhibits HIV-1 Env evolution in primary human cells.

Mesplède T, Moïsi D, Oliveira M, Ibanescu I, Ohnona F, Brenner B, Wainberg MA.

AIDS. 2015 Mar 27;29(6):659-65. doi: 10.1097/QAD.0000000000000606.

PMID:
25849829
6.

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.

Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA, Liang C.

Retrovirology. 2015 Feb 27;12:22. doi: 10.1186/s12977-015-0150-z.

7.

Subtype-Specific Analysis of the K65R Substitution in HIV-1 That Confers Hypersusceptibility to a Novel Nucleotide-Competing Reverse Transcriptase Inhibitor.

Xu HT, Colby-Germinario SP, Quashie PK, Bethell R, Wainberg MA.

Antimicrob Agents Chemother. 2015 Jun;59(6):3189-96. doi: 10.1128/AAC.00315-15. Epub 2015 Mar 16.

PMID:
25779585
8.

Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome.

Wainberg MA.

Clin Infect Dis. 2015 May 15;60(10):1550-1. doi: 10.1093/cid/civ107. Epub 2015 Feb 13. No abstract available.

PMID:
25681379
9.

Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity.

Singhroy DN, Wainberg MA, Mesplède T.

Antimicrob Agents Chemother. 2015 May;59(5):2882-5. doi: 10.1128/AAC.05181-14. Epub 2015 Feb 9.

PMID:
25666155
10.

Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.

Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg MA.

J Virol. 2015 Apr;89(8):4681-4. doi: 10.1128/JVI.03485-14. Epub 2015 Feb 4.

PMID:
25653436
11.

Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.

Wares M, Hassounah S, Mesplède T, Sandstrom PA, Wainberg MA.

Antimicrob Agents Chemother. 2015 Apr;59(4):1942-9. doi: 10.1128/AAC.04829-14. Epub 2015 Jan 12.

PMID:
25583721
12.

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.

Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplède T, Wainberg MA.

J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.

PMID:
25552724
13.

How will the ebola crisis impact the HIV epidemic?

Wainberg MA, Lever AM.

Retrovirology. 2014 Nov 30;11(1):110. doi: 10.1186/s12977-014-0110-z. No abstract available.

14.

HIV and Ebola: similarities and differences.

Wainberg MA, Kippax S, Bras M, Sow PS.

J Int AIDS Soc. 2014 Dec 1;17:19896. doi: 10.7448/IAS.17.1.19896. eCollection 2014. No abstract available.

15.

The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.

Kramer VG, Hassounah S, Colby-Germinario SP, Oliveira M, Lefebvre E, Mesplède T, Wainberg MA.

J Antimicrob Chemother. 2015 Mar;70(3):750-6. doi: 10.1093/jac/dku451. Epub 2014 Nov 27.

PMID:
25433008
16.

The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir.

Cutillas V, Mesplede T, Anstett K, Hassounah S, Wainberg MA.

Antimicrob Agents Chemother. 2015 Jan;59(1):310-6. doi: 10.1128/AAC.04274-14. Epub 2014 Oct 27.

PMID:
25348535
17.

Trichiconins A-C, limonoids with new carbon skeletons from Trichilia connaroides.

Liu CP, Xu JB, Han YS, Wainberg MA, Yue JM.

Org Lett. 2014 Oct 17;16(20):5478-81. doi: 10.1021/ol5027552. Epub 2014 Oct 8.

PMID:
25296007
18.

A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load.

Charest H, Doualla-Bell F, Cantin R, Murphy DG, Lemieux L, Brenner B, Hardy I, Moisi D, Lo E, Baril JG, Wainberg MA, Roger M, Tremblay C.

PLoS One. 2014 Oct 8;9(10):e109420. doi: 10.1371/journal.pone.0109420. eCollection 2014.

19.

Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines.

Quan Y, Xu H, Kramer VG, Han Y, Sloan RD, Wainberg MA.

Virol J. 2014 Oct 6;11:177. doi: 10.1186/1743-422X-11-177.

20.

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.

Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M.

J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3.

PMID:
25281399
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk